INDICATIONS AND USAGE
ZEMIDAPA is a combination of gemigliptin, a dipeptidyl peptidase-4
(DPP-4) inhibitor and dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes(T2D) patients for whom coadministration of gemigliptin and dapagliflozin is appropriate.
DOSAGE AND ADMINISTRATION
The recommended dose of ZEMIDAPA is a 10 mg dapagliflozin/50 mg gemigliptin tablet taken orally once daily, with or without food.
The efficacy and safety of this drug depend on renal function, and it is recommended to periodically assess renal function before and after administration of this drug.
- No dose adjustment is required if the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73 m2 or higher.
- Administration of this drug is not recommended if the estimated glomerular filtration rate (eGFR) is less than 45 mL/min/1.73 m2.
No dose adjustment is required in patients with mild to moderate hepatic impairment. The safety and efficacy of this drug have not been studied in patients with severe hepatic impairment.
Appearance and Packaging Unit
56 tablets/box [(14 tablets/PTP)x4]
Active Ingredient and Capacity
Gemigliptin/Dapagliflozin: 50/10 mg
Storage / Shelf Life
Store in a tight container at room temperature (1 to 30°C)
36 months from the date of manufacturing
Latest revision date of product information